The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense Oligonucleotide (ASO) ...

Then the sunrise was amazing and then you gotta get through the heat and kind of battling through rest of that distance for ...

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin ...

Vertex struck a milestone deal with NHS England to make its cutting-edge cystic fibrosis drug ALYFTREK available to eligible ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Hundreds of cystic fibrosis patients become eligible for ‘life-changing’ therapy - Some people with the rarest forms of the ...

A recent study led by Paul DeCaen, Ph.D., associate professor of Pharmacology, has identified novel molecular mechanisms by ...

Autonomy, confidence and competence were stronger predictors of wellbeing than more traditional measures like deprivation or ...